Yttrium trifluoride

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

14 February 2017 - 23 May 2017

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2017

Report date:

2017

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

Deviations:

no

Test guideline 3

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1100 (Acute Oral Toxicity)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Yttrium trifluoride

EC Number:

237-257-5

EC Name:

Yttrium trifluoride

Cas Number:

13709-49-4

Molecular formula:

YF3

IUPAC Name:

yttrium trifluoride

Test material form:

solid: particulate/powder

Details on test material:

- Name of test material (as cited in study report): yttrium trifluoride
- Physical state: solid
- Appearance: white powder
- Further information on test material confidential.

Specific details on test material used for the study:

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: On the day of administration, the test item was freshly formulated at a concentration of 200 mg/mL in the vehicle (distilled water).
- No correction for purity of the test item was made.

FORM AS APPLIED IN THE TEST (if different from that of starting material): formulation with distilled water at a concentration of 200 mg/mL

Test animals

Species:

rat

Strain:

Wistar

Remarks:

Crl:WI

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Laboratories Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 weeks old
- Weight at treatment: 187-205 g
- Fasting period before study: The night before treatment the animals were fasted for a maximum of 16 hours. Food but not water was withheld overnight. Food was replaced 3 hours after treatment.
- Housing: Standard housing conditions. Group caging (3 animals/cage) in Type II. polypropylene/polycarbonate cages. "Lignocel 3/4-S Hygienic Animal Bedding" and "Arbocel crinklets natural" nest building material, produced by J. Rettenmaier & Söhne GmbH + CO.KG (D-73494 Rosenberg, Germany), were available to the animals during the study.
- Diet (e.g. ad libitum): ad libitum; ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" produced by Ssniff Spezialdiäten GmbH, D-59494 Soest, Germany (Batch number: 484 14771, expiry date: 30 June 2017)
- Water (e.g. ad libitum): Tap water from the municipal supply, as for human consumption, from a 500-mL bottle, ad libitum.
- The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study. Water quality control analysis was performed once every three months and microbiological assessment was performed monthly, by Veszprém County Institute of State Public Health and Medical Officer Service (ÁNTSZ, H-8201 Veszprém, József A. u. 36., Hungary).
- Acclimation period: At least 5 days.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.5 – 23.9°C
- Humidity (%): 36 – 61%
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12 hrs dark/12 hrs light

IN-LIFE PERIOD:
- 14 February 2017 to 28 February 2017 (females no. 6694, 6695, 6696)
- 15 February 2017 to 01 March 2017 (females no. 6697, 6698, 6699)

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

water

Remarks:

distilled

Details on oral exposure:

VEHICLE (distilled water)
- Concentration in vehicle: 200 mg/mL
- Justification for choice of vehicle: no data
- Lot/batch no. (if required): 7600914

MAXIMUM DOSE VOLUME APPLIED: 10mL/kg

DOSAGE PREPARATION (if unusual): Freshly formulated on the day of administration at a concentration of 200 mg/mL in vehicle (distilled water). The formulation container was magetically stirred continuously up to the end of the dose administration procedures. The test item formulation was used within 4 hours of preparation.

CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: The initial dose level was selected by the Study Director to be that which is most likely to produce mortality in some of the dosed animals. In the lack of any preliminary toxicological information, 2000 mg/kg bw was selected to be the starting dose. Initially, three female animals were treated with the test item at a dose level of 2000 mg/kg bw. No mortality was observed, therefore a further 3 animals were treated at the dose level of 2000 mg/kg bw. As no mortality was observed in this second dose group, further testing was not required according to the test guidelines.

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

3 females per group, 2 groups

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
*Clinical signs: Animals were observed individually after dosing at 30 minutes, then 1, 2, 3, 4 and 6 hours after dosing and daily for 14 consecutive days thereafter.
*Individual observations were performed on the skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
*Body weight: The body weight was recorded on the day before treatment (Day -1), on the day of the treatment (Day 0), weekly thereafter (Day 7) and at necropsy (Day 14).
- Necropsy of survivors performed: Yes. The animals were sacrificed by exsanguination under pentobarbital anaesthesia. All animals were subjected to necropsy and a macroscopic examination. After examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs were observed. All gross macroscopic changes were recorded for each animal.

Statistics:

No statistical analysis was performed.

Results and discussion

Effect levels

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

The test item did not cause mortality at a dose level of 2000 mg/kg bw.

Clinical signs:

All animals were symptom-free during the observation period.

Body weight:

Body weight gains of treated animals during the study showed no indication of a test item-related effect.

Gross pathology:

There was no evidence of macroscopic changes at a dose level of 2000 mg/kg bw in any animal.

Other findings:

No additional information.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

Under the conditions of the study, the acute oral LD50 value of yttrium trifluoride was found to be > 2000 mg/kg bw in female Crl:(WI) rats. According to these results, yttrium trifluoride needs not to be classified according to CLP criteria.